Advances in Hematology

Review Article

The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-Cell Lymphoma

Table 1

Phase III trials of HDT/ASCT in CR or PR unfavorable NHL patients.
AuthorYear Histological classificationDLCL (%)Immunological phenotype (%)aaIPI ≥ 2 (%)Disease status HDT/ASCTTherapyShorten induction Yes/NoPFS/EFS (%) OS (%)
Verdonk [12] 199535
34		 W.F.26
33		B: 77
B: 79		44
44		 PR CHOP × 8 versus CHOP × 4 + HD-CTX-TBI/ASCT Yes4y: 53
4y: 41		 N.S.4y: 85
4y: 56		 N.S.
Martelli [13] 199627 22 W.F./Kiel62
40		B: 70
B: 45		N.R. PR DHAP1 × 6 versus BEAC1/ASCT No5y: 52
5y: 73		 N.S.59
73		 N.S.
Haioun [14] 2000111
125		 W.F.61
56		B: 63
B: 60		90
80		 CR ACVB  versus ACVB + CBV/ASCT No8y: 39
8y: 55		0.028y: 49
8y: 64		0.04
Kluin-Nelemans [15] 200156
49		 REAL58
50		B: 55
B: 66		29
31		 CR, PR ChVmP/BV1 × 8 versus ChVmP/BV1 × 6 + BEAM/ASCT Yes5y: 56
5y: 61		N.S.5y: 77
5y: 68		N.S.
Milpied [16] 200499
98		 W.F.74
77		B: 74
B: 77		49
57		 PR ACBVP2 versus CEOP + ECVBP2 + BEAM/ASCT No5y: 37
5y: 55		0.0375y: 56
5y: 71		N.S.
1Plus radiotherapy at bulky disease.
2Plus radiotherapy at bulky disease and intrathecal prophylaxis in very high-risk patients.
W.F.: working formulation—NHL classification; Kiel: Kiel classification of NHL; CR: complete response; PR: partial response; CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone; HD-CTX: high-dose cyclophosphamide; TBI: total body irradiation; DHAP: cisplatin, cytarabine, and high-dose dexamethasone; BEAC: carmustine, etoposide, cytarabine, and cyclophosphamide; ACBV: doxorubicin, cyclophosphamide, vindesine, and bleomycin; CBV: cyclophosphamide, vinblastine, and bleomycin; ChVmP/BV: cyclophosphamide, doxorubicin, teniposide, prednisone, bleomycin, and vincristine; BEAM: carmustine, etoposide, cytarabine, and melphalan; CEOP: cyclophosphamide, epirubicin, vincristine, and prednisone; ECVBP: epirubicin, cyclophosphamide, vindesine, bleomycin, and prednisone; N.S.: not significant.